Effects of seasonal and pandemic influenza on health-related quality of life, work and school absence in England: Results from the Flu Watch cohort study

Influenza and other Respiratory Viruses

Volumn 12, Issue 1, 2018, Pages 171-182

  Fragaszy, Ellen B ^a,b   Warren Gash, Charlotte ^b   White, Peter J ^c,d   Zambon, Maria ^d   Edmunds, William J ^b   Nguyen Van Tam, Jonathan S ^e   Hayward, Andrew C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

costs and cost analysis; EQ 5D; human; influenza; quality of life; respiratory tract infections; work and school absences

Indexed keywords

ABSENTEEISM; ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; ENGLAND; FEMALE; HUMAN; INFLUENZA A; INFLUENZA B; MAJOR CLINICAL STUDY; MALE; NOSE SMEAR; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; SCHOOL ATTENDANCE; SEASONAL INFLUENZA; SEASONAL VARIATION; SUMMER; WINTER; CHILD; COST OF ILLNESS; INFANT; INFLUENZA; MIDDLE AGED; PANDEMIC; PRESCHOOL CHILD; SCHOOL; SEASON; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COST OF ILLNESS; ENGLAND; HUMANS; INFANT; INFLUENZA, HUMAN; MIDDLE AGED; PANDEMICS; QUALITY OF LIFE; SCHOOLS; SEASONS; YOUNG ADULT;

EID: 85042316551     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12506     Document Type: Article

References (24)

1. Thorrington D, Balasegaram S, Cleary P, Hay C, Eames K. Social and economic impacts of school influenza outbreaks in England: survey of caregivers. J Sch Health. 2017;87:209-16.
2. Chow MY, Morrow AM, Booy R, Leask J. Impact of children's influenza-like illnesses on parental quality of life: a qualitative study. J Paediatr Child Health. 2013;49:664-70.
3. National Institute of Health and Care Excellence. Guide to the methods of technology appraisal 2013. https://www.nice.org.uk/process/pmg9. Accessed September 12, 2017.
4. Szende A, Williams A, EuroQol Group. Measuring Self-Reported Population Health: An International Perspective Based on EQ5D. Hungary: SpringMed Publishing, 2004.
5. van Hoek AJ, Underwood A, Jit M, Miller E, Edmunds WJ. The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study. PLoS One. 2011;6: e17030.
6. Griffin AD, Perry AS, Fleming DM. Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. Pharmacoeconomics. 2001;19:293-301.
7. Prosser LA, Bridges CB, Uyeki TM, et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis. 2006;12(10):1548-58.
8. Sander B, Kwong JC, Bauch CT, et al. Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med. 2010;7:e1000256.
9. Siddiqui MR, Edmunds WJ. Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerg Infect Dis. 2008;14:267-74.
10. Antonova EN, Rycroft CE, Ambrose CS, Heikkinen T, Principi N. Burden of paediatric influenza in Western Europe: a systematic review. BMC Public Health. 2012;12:968.
11. Hollmann M, Garin O, Galante M, Ferrer M, Dominguez A, Alonso J. Impact of influenza on health-related quality of life among confirmed (H1N1)2009 patients. PLoS One. 2013;8:e60477.
12. Hayward AC, Fragaszy EB, Bermingham A, et al. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir Med. 2014;2:445-54.
13. Fragaszy EB, Warren-Gash C, Wang L, et al. Cohort profile: the Flu Watch study. Int J Epidemiol. 2017;46:e18.
14. Ellis J, Iturriza M, Allen R, et al. Evaluation of four real-time PCR assays for detection of influenza A(H1N1)v viruses. Eurosurveillance. 2009;14:19230.
15. Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis. 2009;48:389-96.
16. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53-72.
17. Group E. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
18. Szende A, Oppe M, Devlin N. EQ-5D Value Sets: Inventory. Dordrecht: Comparative Review and User Guide; 2007.
19. Office for National Statistics. Annual Mid-Year Population Estimates for England & Wales, Mid-2011. http://webarchive.nationalarchives.gov.uk/20160108124536/http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-england-and-wales/mid-2011--2011-census-based-/stb---mid-2011-census-based-population-estimates-for-england-and-wales.html. Accessed September 12, 2017.
20. O'Brien BJ, Goeree R, Blackhouse G, Smieja M, Loeb M. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada. Value Health. 2003;6:116-25.
21. Bilcke J, Coenen S, Beutels P. Influenza-like-illness and clinically diagnosed flu: disease burden, costs and quality of life for patients seeking ambulatory care or no professional care at all. PLoS One. 2014;9:e102634.
22. Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med. 2002;156:986-91.
23. Saigal S, Stoskopf BL, Feeny D, et al. Differences in preferences for neonatal outcomes among health care professionals, parents, and adolescents. JAMA. 1999;281:1991-7.
24. Prosser LA. Current challenges and future research in measuring preferences for pediatric health outcomes. J Pediatr. 2009;155:7-9.